Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia
- 1.2k Downloads
Community-acquired pneumonia (CAP) is a major source of sepsis, and sepsis-related acute organ dysfunction determines patient outcome. Therefore, early risk stratification using clinical scores such as the CRB(-65) and subsequent evaluation for organ dysfunction to identify high-risk patients should be the standard of care . For sepsis, new criteria (Sepsis-3) have recently been proposed including a qSOFA score as a rapid screening tool . The qSOFA was validated within various datasets of heterogeneous sepsis patients  and consists of the same three clinical parameters used in CRB but with different cut-offs for tachypnea (respiratory rate ≥22/min vs. ≥30/min in CRB) and hypotension (systolic blood pressure ≤100 mmHg vs. <90 mmHgsys or ≤60 mmHgdias) [2, 4]. A cut-off of ≥2 qSOFA-criteria provided mortality prediction as good as the more complex SOFA score in non-ICU patients. However, the original datasets used to establish qSOFA were not stratified according to...
KeywordsOrgan Dysfunction Sofa Score Mortality Prediction Multicenter Validation Acute Organ Dysfunction
Grants: CAPNETZ was founded by a BMBF Grant (01KI07145) 2001-2011. CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network has only been made possible by the contribution of many investigators. We are especially indebted to the work of the investigators in the local clinical centers (LCC) who established and kept contact to all practitioners, physicians, and respiratory specialists cooperating within the network. Members of the CAPNETZ study group except the authors: M. Dreher, C. Cornelissen (Aachen); W. Knüppel (Bad Arolsen); D. Stolz (Basel); N. Suttorp, P. Creutz (Berlin, Charité); T. Bauer, T. Sabha (Berlin); W. Pankow, A. Lies, D. Thiemig (Berlin-Neukölln); B. Hauptmeier, S. Ewig, D. Wehde (Bochum); M. Prediger, S. Schmager (Cottbus); G. Höffken, M. Kolditz, B. Schulte-Hubbert, S. Langner (Dresden), T. Welte, G. Barten, M. Abrahamczik, J. Naim, W. Kröner, T. Illig, N. Klopp (Hannover); P. Ravn, A. Vestergaard-Jensen, G. Baunbaek-Knudsen (Hillerød); C. Kroegel, M. Pletz, J. Happe, J. Frosinski, J. Winning, A. Moeser (Jena); K. Dalhoff, K. Dageförde, K. Franzen, F. Hyzy, H. Schmieg, P. Parschke, P. Thiemann, J. Ahrens, T. Hardel (Lübeck); G. Rohde, J. Drijkoningen (Maastricht); H. Buschmann, R. Kröning (Paderborn); H. Schütte (Potsdam), T. Schaberg, I. Hering (Rotenburg/Wümme); C. Kropf-Sanchen (Ulm); T. Illmann, M. Wallner (Ulm); and all study nurses.
Compliance with ethical standards
Conflicts of interest
Dr. Kolditz reports personal fees from Pfizer, Gilead, Novartis, Astra-Zeneca, Basilea, Böhringer-Ingelheim, Bayer, outside the submitted work. Dr. Scherag reports grants from Federal Ministry of Education and Research (BMBF), Germany, during the conduct of the study. Dr. Rohde reports personal fees from Pfizer, Novartis, Bayer, Astra Zeneca and Chiesi outside the submitted work. Dr. Welte reports grants from Ministry of Research and Education, during the conduct of the study; personal fees from AstraZeneca, Bayer, Basilea, Infectopharm, Pfizer, outside the submitted work. Dr. Ewig and Dr. Pletz have nothing to disclose.